GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase
Additional Shares
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of
its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters
of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered
by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts
and commissions and offering expenses, were approximately $92.6 million.
Jefferies LLC and Cowen acted as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. acted as lead
manager for the offering.
A shelf registration statement relating to this offering was filed with the Securities and Exchange Commission (SEC)
on March 17, 2015 and declared effective by the SEC on March 24, 2015. The offering was made only by means
of a written prospectus and prospectus supplement that form a part of the registration statement. The final prospectus supplement
and accompanying prospectus were filed with the SEC on May 24, 2017. Copies of the final prospectus supplement and the
accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 821-7388;
or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717,
Attention: Prospectus Department, or by phone at (631) 274-2806.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell
disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being
evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple
myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital
Region.
GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media Contact:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530006192/en/